Merck & Co., Inc: Hyperlipoproteinemia Type II trials

The registry lists 17 Hyperlipoproteinemia Type II studies with Merck & Co., Inc as lead sponsor. 1 are open to participants now and 9 have results posted.

Phase 1 2Phase 2 4Phase 3 13(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)RecruitingNCT07058077Phase 2/3
• A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)CompletedNCT05952869Phase 3Results posted
• A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef LipidsCompletedNCT05952856Phase 3Results posted
• A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)CompletedNCT05261126Phase 2Results posted
• A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)TerminatedNCT01583647Phase 1Results posted
• Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)CompletedNCT01524289Phase 3Results posted
• A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)CompletedNCT01012219Phase 1Results posted
• Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)CompletedNCT00941603Phase 2Results posted
• Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED)TerminatedNCT00384293Phase 3Results posted
• Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)CompletedNCT00289900Phase 3Results posted
• Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)TerminatedNCT01841684Phase 3
• A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)CompletedNCT01824238Phase 3
• Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)CompletedNCT00378833Phase 3
• Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)CompletedNCT00376584Phase 3
• Lipid Efficacy Study (0524B-022)(COMPLETED)CompletedNCT00269217Phase 3
• Lipid Efficacy/Tolerability Study (0524A-020)CompletedNCT00269204Phase 3
• MARS - Monitored Atherosclerosis Regression StudyCompletedNCT00116870Phase 2/3